Olamufloxacin | CAS#167887-97-0 | antibacterial

MedKoo Cat#: 584929 | Name: Olamufloxacin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Olamufloxacin is a fluoroquinolone antibacterial.

Chemical Structure

Olamufloxacin

CAS#167887-97-0

Theoretical Analysis

MedKoo Cat#: 584929

Name: Olamufloxacin

CAS#: 167887-97-0

Chemical Formula: C20H23FN4O3

Exact Mass: 386.1754

Molecular Weight: 386.43

Elemental Analysis: C, 62.16; H, 6.00; F, 4.92; N, 14.50; O, 12.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Olamufloxacin; HSR 903; HSR-903; HSR903

IUPAC/Chemical Name

3-Quinolinecarboxylic acid, 5-amino-7-(7-amino-5-azaspiro(2,4)hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxo-, (S)-

InChi Key

LEILBPMISZFZQK-GFCCVEGCSA-N

InChi Code

InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1

SMILES Code

O=C(C1=CN(C2CC2)C3=C(C(N)=C(F)C(N(C[C@H]4N)CC54CC5)=C3C)C1=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 386.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sun J, Deguchi Y, Tauchi Y, He Z, Cheng G, Morimoto K. Distribution characteristics of orally administered olamufloxacin, a newly synthesized fluoroquinolone antibacterial, in lung epithelial lining fluid and alveolar macrophage in rats. Eur J Pharm Biopharm. 2006 Oct;64(2):238-45. Epub 2006 Jun 23. PubMed PMID: 16875808. 2: Sun J, Sakai S, Tauchi Y, Deguchi Y, Cheng G, Chen J, Morimoto K. Protonation equilibrium and lipophilicity of olamufloxacin (HSR-903), a newly synthesized fluoroquinolone antibacterial. Eur J Pharm Biopharm. 2003 Sep;56(2):223-9. PubMed PMID: 12957636. 3: Yoshizumi S, Takahashi Y, Murata M, Domon H, Furuya N, Ishii Y, Matsumoto T, Ohno A, Tateda K, Miyazaki S, Yamaguchi K. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. J Antimicrob Chemother. 2001 Jul;48(1):137-40. PubMed PMID: 11418525. 4: Jiraskova N. Olamufloxacin. Hokuriku Seiyaku. Curr Opin Investig Drugs. 2000 Sep;1(1):31-4. Review. PubMed PMID: 11249592. 5: Higa F, Arakaki N, Tateyama M, Koide M, Shinzato T, Kawakami K, Saito A. In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. J Antimicrob Chemother. 2003 Dec;52(6):920-4. Epub 2003 Nov 12. PubMed PMID: 14613952. 6: Chalyk BA, Butko MV, Yanshyna OO, Gavrilenko KS, Druzhenko TV, Mykhailiuk PK. Synthesis of Spirocyclic Pyrrolidines: Advanced Building Blocks for Drug Discovery. Chemistry. 2017 Nov 27;23(66):16782-16786. doi: 10.1002/chem.201702362. Epub 2017 Oct 10. PubMed PMID: 28800185. 7: Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000 Nov;89(11):1371-88. Review. PubMed PMID: 11015683. 8: Yoshizumi S, Takahashi Y, Watanabe Y, Okezaki E, Ishii Y, Tateda K. In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC. Chemotherapy. 2004 Dec;50(6):265-75. Epub 2004 Dec 8. PubMed PMID: 15608441. 9: Takahashi Y, Masuda N, Otsuki M, Miki M, Nishino T. In vitro activity of HSR-903, a new quinolone. Antimicrob Agents Chemother. 1997 Jun;41(6):1326-30. PubMed PMID: 9174193; PubMed Central PMCID: PMC163909. 10: Yoshizumi S, Domon H, Miyazaki S, Yamaguchi K. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Antimicrob Agents Chemother. 1998 Apr;42(4):785-8. PubMed PMID: 9559783; PubMed Central PMCID: PMC105542. 11: Frean J, Klugman KP, Arntzen L, Bukofzer S. Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. J Antimicrob Chemother. 2003 Aug;52(2):294-6. Epub 2003 Jul 15. PubMed PMID: 12865386. 12: Niki Y, Watanabe S, Tamada S, Yoshida K, Miyashita N, Nakajima M, Matsushima T, Sekino H, Matsuoka O. Effect of HSR-903, a new fluoroquinolone, on the concentration of theophylline in serum. Antimicrob Agents Chemother. 1999 Jun;43(6):1494-6. PubMed PMID: 10348779; PubMed Central PMCID: PMC89305. 13: Niki Y, Miyashita N, Kubota Y, Nakajima M, Matsushima T. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. Antimicrob Agents Chemother. 1997 Apr;41(4):857-9. PubMed PMID: 9087506; PubMed Central PMCID: PMC163811. 14: Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob Agents Chemother. 2000 Jan;44(1):192-5. PubMed PMID: 10602748; PubMed Central PMCID: PMC89653. 15: Murata M, Tamai I, Sai Y, Nagata O, Kato H, Tsuji A. Carrier-mediated lung distribution of HSR-903, a new quinolone antibacterial agent. J Pharmacol Exp Ther. 1999 Apr;289(1):79-84. PubMed PMID: 10086990. 16: Murata M, Tamai I, Sai Y, Nagata O, Kato H, Sugiyama Y, Tsuji A. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab Dispos. 1998 Nov;26(11):1113-9. PubMed PMID: 9806954. 17: Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. 1999 Dec;43(12):3001-4. PubMed PMID: 10582897; PubMed Central PMCID: PMC89602. 18: Murata M, Tamai I, Kato H, Nagata O, Tsuji A. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J Pharmacol Exp Ther. 1999 Jul;290(1):51-7. PubMed PMID: 10381759. 19: Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, Fujimura S, Nukiwa T. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections. Antimicrob Agents Chemother. 1999 Jul;43(7):1767-8. PubMed PMID: 10390240; PubMed Central PMCID: PMC89361. 20: Deguchi T, Yasuda M, Ishihara S, Takahashi Y, Okezaki E, Nagata O, Saito I, Kawada Y. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC. J Antimicrob Chemother. 1997 Sep;40(3):437-9. PubMed PMID: 9338500.